Previous 10 | Next 10 |
HC Wainwright has initiated coverage of DICE Therapeutics ( NASDAQ: DICE ) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling ...
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...
The following slide deck was published by DICE Therapeutics, Inc. in conjunction with this event. For further details see: DICE Therapeutics (DICE) Investor Presentation - Slideshow
DICE Therapeutics press release (NASDAQ:DICE): Q1 GAAP EPS of -$0.50. Cash, cash equivalents and marketable securities totaled $303.2 million at March 31, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milestones. For furthe...
Topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients expected in mid-2022 Current cash provides runway through mid-2024 and multiple expected key clinical milestones SOUTH SAN FRANCISCO, Calif., Ma...
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therape...
DICE Therapeutics Inc. (NASDAQ:DICE) traded at a new 52-week high today of $40.50. So far today approximately 1 million shares have been exchanged, as compared to an average 30-day volume of 331,000 shares. DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary techn...
DICE Therapeutics press release (NASDAQ:DICE): Q4 GAAP EPS of -$0.44 beats by $0.19. Cash, cash equivalents and marketable securities totaled $319.3 million at December 31, 2021. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical milest...
On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022 Named development candidate DC-853 from the novel scaffold program 1 series of oral IL-17 franchise Current cash p...
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...
News, Short Squeeze, Breakout and More Instantly...
DICE Therapeutics Inc. Company Name:
DICE Stock Symbol:
NASDAQ Market:
DICE Therapeutics Inc. Website:
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...